Allison Zwingenberger

Omniox, Inc.

$505,594

Attributed

$1,735,771

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $602.7K · FY2017–20

$1M$750K$500K$250K$0

'17

'18

'19

'20

Funding mix

By agency

NIH$1,735,771 · 1

By mechanism

R01$1,735,771 · 1

Top collaborators

Most similar at Omniox, Inc.

Same institution · by research overlap

Ajit S Shah$6,420,002
Ana Krtolica$1,680,034
Jonathan A Winger$3,362,152
Stephen Cary$1,668,893
Michael Sean Kent$648,464

Others in their field

Other Emerging Leaders on “Clinical Trials”

Sonia M Thomas · Research Triangle Institute$700,865,642
Bambra Strokes · Ppd Development Lp$526,656,217
Tracy L Nolen · Research Triangle Institute$474,487,152
Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785

Research focus

Clinical TrialsAnimalsAffinityClinical ResearchBiochemicalBiological MarkersBiological SciencesAwardAdjuvantBrainBrain ImagingBrain NeoplasmsCaliforniaCancer ImagingCancer PatientCandidate MarkerCanis FamiliarisCarrier ProteinsBlood VesselsBindingCherry - DietaryClinically RelevantClinically TranslatableCohort

Grant awards (4)

Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$704

R01 · FY2020 · CA

Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$546,766

R01 · FY2019 · CA

Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$585,583

R01 · FY2018 · CA

Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$602,718

R01 · FY2017 · CA